Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
4
|
| gptkbp:bfsParent |
gptkb:Trikafta
|
| gptkbp:activities |
CFTR modulator
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:can_be_used_with |
gptkb:ivacaftor
|
| gptkbp:clinical_trial |
Phase 3
approximately 80% |
| gptkbp:contraindication |
hypersensitivity
|
| gptkbp:developed_by |
gptkb:Vertex_Pharmaceuticals
|
| gptkbp:dosage_form |
gptkb:tablet
|
| gptkbp:formulation |
combination with ivacaftor
|
| https://www.w3.org/2000/01/rdf-schema#label |
tezacaftor
|
| gptkbp:indication |
for patients with specific mutations
|
| gptkbp:ingredients |
C22 H26 F2 N2 O3 S
|
| gptkbp:invention |
patented
|
| gptkbp:is_atype_of |
R07 AX
|
| gptkbp:is_used_for |
gptkb:cystic_fibrosis
|
| gptkbp:manager |
oral
|
| gptkbp:marketed_as |
gptkb:Symdeko
|
| gptkbp:side_effect |
fatigue
headache nausea diarrhea |
| gptkbp:targets |
CFTR protein
|
| gptkbp:treatment |
with ivacaftor
|
| gptkbp:type_of |
1626354-69-0
|
| gptkbp:weight |
420.52 g/mol
|
| gptkbp:year |
gptkb:2018
|